Search Results

April is the month of DNA Day, a special day commemorating the discovery of the DNA double helix structure The discovery of DNA's double helical structure was a scientific milestone that revolutionized molecular Genomics, in turn, played a crucial role in the discovery and sequencing of the beta-adrenergic receptor Additionally, there have been recent discoveries of the conformational changes that occur during G-protein discovery and design targeting GPCRs, leading to the development of novel therapeutics.

binding partners on the GPCR activation mechanism, which should be taken into account in structure-based drug discovery.

Illuminating GPCR signaling mechanisms by NMR spectroscopy with stable-isotope labeled receptors GPCR Binders, Drugs worth up to $674M 2023 Half-Year Financial Results and Exciting Developments at Aelis Farma Ion Channel Drug Chair of its Board of Directors Novo Nordisk and Evotec collaborate to launch LAB eN², a translational drug discovery accelerator, to address innovation gap in cardiometabolic diseases GPCR Events, Meetings, 2024 Conference and Exhibition June 2 - 4, 2024 | Chemotactic Cytokines GPCR Jobs NEW In vivo Antibody Discovery

inhibiting GRP75-mediated endoplasmic reticulum-mitochondrial coupling in diabetic retinopathy GPCR Binders, Drugs classifications and refinements in high-resolution single particle cryo-EM analysis Structure-based drug discovery of a corticotropin-releasing hormone receptor 1 antagonist using an X-ray free-electron laser Deadline September 27, 2023 GPCR Events, Meetings, and Webinars September 25 - 28, 2023 | Discovery On Target September 27 - 28, 2023 | Training Seminar "The Renaissance in GPCRs as Drug Targets: Allosteric

GPCR Binders, Drugs, and more Design of Drug Efficacy Guided by Free Energy Simulations of the β2-Adrenoceptor New paradigms in purinergic receptor ligand discovery. Anticancer Therapy An extraordinary opportunity to generate proprietary chemo-informatics for GPCR drug discovery - Design Pharmaceuticals Call for GPCR Papers GPCRs: Signal Transduction. Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.

November 25 - 27, 2024 | 1st Virtual GPCR Forum Conference November 26 - 28, 2024 | GPCRs-Targeted Drug Discovery Summit Europe July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology self-renewal and pluripotency of mouse embryonic stem cells via JAK1/STAT3 signaling pathway GPCR Binders, Drugs and more Global analysis of neuropeptide receptor conservation across phylum Nematoda Target-based discovery

GPCR Binders, Drugs, and more ACE2 Activation by Tripeptide IRW (Ile-Arg-Trp) Depends on the G Protein-Coupled Ions Regulating Agonist and Antagonist Binding in the Active Site of a Novel Target 5HT2BR Against Drug-Resistant Application of computational methods for class A GPCR Ligand discovery. New paradigms in purinergic receptor ligand discovery. GPCR Events, Meetings, and Webinars FREE Symposium - IPI Surfacing (June 15, 2023) GPCRs in drug discovery

GPCR Binders, Drugs, and more Altered signaling at the PTH receptor via modified agonist contacts with Establishment of a CaCC-based Cell Model and Method for High-throughput Screening of M3 Receptor Drugs GPCR Events, Meetings, and Webinars 2nd GPCR-Targeted Drug Discovery Summit | February 21-23, Boston. Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.

agonist-driven regulation of the neurokinin 1 receptor using a GPCR phosphorylation immunoassay GPCR Binders, Drugs the treatment of cannabis use disorder Orion Biotechnology will be presenting at the 19th Biopharma Drug Discovery Nexus Salipro Biotech will participate in BioKorea2024 Domain Therapeutics Appoints Sean A

their research on Virtual Screening of a Chemically Diverse "Superscaffold" Library Enables Ligand Discovery peptide-induced relaxation of human coronary arteries: A key role for Gβγ subunit instead of cAMP GPCR Binders, Drugs , and more Virtual Screening of a Chemically Diverse "Superscaffold" Library Enables Ligand Discovery next-generation medicines G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery Frizzleds act as dynamic pharmacological entities Structural and Molecular Insights into GPCR

GPCR Binders, Drugs, and more Engineered Human Antibody with Improved Endothelin Receptor Type A Binding A robust antibody discovery platform for difficult-to-express G protein-coupled receptors. Identification of a potential structure-based GPCR drug for interstitial cystitis/bladder pain syndrome GPCR Events, Meetings, and Webinars 2nd GPCR-Targeted Drug Discovery Summit | February 21-23, Boston. Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.

better tools to study its function in both disease and physiological settings will likely potentiate drug discovery campaigns against this orphan GPCR.

One such platform is the chemogenetic DREADD (designer receptor exclusively activated by designer drugs

August 2022 "Join Us in Boston for Discovery On Target 2022! Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents

October 2022 Discovery and In Vivo Evaluation of ACT-660602: A Potent and Selective Antagonist of the high-throughput screening hit, we describe the iterative optimization of a chemical series culminating in the discovery

What This Means for CB2 Drug Discovery Programs Taken together, the dataset offers several insights into how live-cell HCS can support CB2 ligand discovery: 1.

December 2022 Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in GPCR-focused structure-based drug

receptors (GPCRs) revealed the location of allosteric binding sites and opened new opportunities for the discovery access to high-resolution structures of GPCRs in complex with allosteric modulators can accelerate lead discovery

receptors (GPCRs) revealed the location of allosteric binding sites and opened new opportunities for the discovery access to high-resolution structures of GPCRs in complex with allosteric modulators can accelerate lead discovery

Drug discovery today, 24(11), 2192–2201. https://doi.org/10.1016/j.drudis.2019.09.003 Ferrandon, S., Functional selectivity of GPCR-directed drug action through location bias.

What are the implications in drug discovery?

In this study, we report the discovery of a novel lead compound for S1R binding, based on the thiazolidine

In discovery, different pathways may look identical at first glance. The first trap in discovery is stopping at description. You’ll know how to use them to sharpen discovery decisions. It’s a shift in how you approach discovery. Built for discovery-phase teams, pharmacologists refining fundamentals, scientists challenging legacy

And potential drug candidates left behind. From oxymetazoline to oxotremorine, discover how drugs can show up as full agonists in one system and If you're an emerging drug hunter, this lesson is your bridge from data confusion to predictive clarity

faster than medicine can adapt, Catherine’s work shows why overdose research must evolve alongside the drug A Crisis That’s Redefining Overdose In 2023, more than 107,000 Americans died from drug overdoses , the On their own, each drug weakens breathing. Together, they don’t just accumulate—they potentiate. It’s about a fundamental collapse of the cycle itself: one drug blocking air from entering, the other The insight is simple but urgent: the drug supply evolves faster than medicine.  

Sometimes when you’re in the field you forget the importance GPCRs holds in drug development as a whole This talk gave a general idea of what goes into designing small molecule drugs, using state-of-the-art She gave us an overview of the drugs she has participated in developing throughout her career, highlighting ’ talk, which talked about new and innovative technologies used to overcome peptides limitations as drugs Several of the drugs shown throughout the conference are starting their clinical trials.

GPCR targeting drugs: orthosteric vs allosteric sites Most of the drugs targeting GPCRs bind to the orthosteric Despite the existence of numerous drugs designed for this primary binding site, there are significant Over the past decade, there has been a notable growth in the discovery of allosteric modulators for GPCRs This variability in drug effects is due to different ligands inducing unique GPCR conformations that To understand how ligands or drugs affect GPCRs is crucial to grasp the dynamics of these conformational

states Apelin receptor dimerization and oligomerization Molecular Insights into GPCR Mechanisms for Drugs Clinical Pharmacology Sosei and Cancer Research UK announce first patient dosed with oral immunotherapy drug Symposium (August 31 - September 1, 2023) 3rd Transatlantic ECI GPCR Symposium (September 7 - 8, 2023) Discovery On Target - DOT (September 25 - 28, 2023) Training Seminar "The Renaissance in GPCRs as Drug Targets Scientist/Senior Scientist I - Molecular Pharmacology Director, Clinical Data Management Director, Discovery

Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug Symposium (August 31 - September 1, 2023) 3rd Transatlantic ECI GPCR Symposium (September 7 - 8, 2023) Discovery On Target - DOT (September 25 - 28, 2023) Training Seminar "The Renaissance in GPCRs as Drug Targets November 15 -17, 2023) ASCEPT Annual Scientific Meeting (November 20 -23, 2023) Structure, Mechanism, and Drug Scientist/Senior Scientist I - Molecular Pharmacology Director, Clinical Data Management Director, Discovery

She found herself drawn toward the science behind the drugs, rather than their clinical application. She uses whole-body plethysmography and pulse oximetry to dissect the specific ways these drugs impact Passion can lead to groundbreaking discoveries and a fulfilling career. Conclusion: A Journey of Self-Discovery Catherine Demery's story is one of self-discovery and resilience